Market Closed - Japan Exchange 12:00:00 03/07/2026 pm IST 5-day change 1st Jan Change
1,558.50 JPY -0.48% Intraday chart for Nipro Corporation -3.94% +5.52%

Valuation: Nipro Corporation

Market Cap 25TCr 157.61Cr 137.78Cr 126.62Cr 118.02Cr 223.86Cr 15TCr 227.25Cr 1.52TCr 590.93Cr 7.38TCr 591.59Cr 578.89Cr P/E 2026
18.7x
P/E 2027 * 19.2x
Enterprise Value 75TCr 464.79Cr 406.32Cr 373.41Cr 348.06Cr 660.16Cr 44TCr 670.18Cr 4.48TCr 1.74TCr 22TCr 1.74TCr 1.71TCr EV / Sales 2026
1.21x
EV / Sales 2027 * 1.1x
Free-Float
87.38%
Yield 2026
1.87%
Yield 2027 * 2.13%
12/05 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 CI
12/05 Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027 CI
01/05 Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold MT
11/03 Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend MT
09/02 Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
24/12 Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore CI
10/11 Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025 CI
10/25/10 Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan MT
09/25/09 Samsung Bioepis Co., Ltd. Enters into A Strategic Partnership with NIPRO Corporation for Commercialization of Multiple Biosimilars in Japan CI
13/25/13 Jefferies Adjusts Nipro's Price Target to 1,300 Yen from 1,400 Yen, Keeps at Hold MT
12/25/12 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2025 and Fiscal Year Ending March 31, 2026 CI
12/25/12 Nipro Corporation Announces Dividend for the Year Ended March 31, 2025, Effective June 27, 2025; Provides Dividend Guidance for the Second Quarter End of Fiscal Year Ending March 31, 2026 CI
12/25/12 Nipro Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026 CI
1 day-0.48%
1 week-3.94%
Current month-1.14%
1 month-8.97%
3 months-3.53%
6 months+5.52%
Current year+5.52%
1 week 1,531
Extreme 1531
1,635
1 month 1,531
Extreme 1531
1,754.5
Current year 1,401
Extreme 1401
1,760.5
1 year 1,304
Extreme 1304
1,760.5
3 years 1,001.5
Extreme 1001.5
1,760.5
5 years 987
Extreme 987
1,760.5
10 years 908
Extreme 908
1,760.5
Manager TitleAgeSince
President 58 26/06/2025
Chief Administrative Officer 57 26/06/2025
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman 81 26/06/2025
Director/Board Member 53 01/06/2009
Director/Board Member 58 01/06/2009
Change 5-day change 1-year change 3-year change Capi.($)
-0.48%-3.94%+19.75%+52.87% 158.74Cr
+3.49%+2.32%-28.86%-12.49% 17TCr
-1.43%+3.32%-5.77%-5.57% 11TCr
+2.80%+3.33%+1.83%+54.09% 5.77TCr
+1.33%-0.73%+56.39%+51.86% 5.32TCr
+0.30%+4.43%-10.83%-40.12% 4.36TCr
+3.50%+14.35% - - 3.65TCr
-1.21%+3.79%-14.75%-44.56% 2.75TCr
+0.55%+5.53%+65.33%-4.37% 2.58TCr
-9.53%+3.61%-8.42%-3.01% 2.13TCr
Average +2.55%+3.38%+8.30%+5.41% 5.4TCr
Weighted average by Cap. +3.30%+3.27%-3.26%+0.29%

Financials

2026 2027 *
Net sales 66TCr 410.17Cr 358.57Cr 329.52Cr 307.15Cr 582.58Cr 39TCr 591.42Cr 3.96TCr 1.54TCr 19TCr 1.54TCr 1.51TCr 70TCr 431.46Cr 377.18Cr 346.63Cr 323.1Cr 612.82Cr 41TCr 622.12Cr 4.16TCr 1.62TCr 20TCr 1.62TCr 1.58TCr
Net income 1.46TCr 9.08Cr 7.94Cr 7.3Cr 6.8Cr 13Cr 864.81Cr 13Cr 88Cr 34Cr 425.1Cr 34Cr 33Cr 1.37TCr 8.53Cr 7.45Cr 6.85Cr 6.38Cr 12Cr 811.74Cr 12Cr 82Cr 32Cr 399.01Cr 32Cr 31Cr
Net Debt 50TCr 307.18Cr 268.54Cr 246.79Cr 230.03Cr 436.31Cr 29TCr 442.92Cr 2.96TCr 1.15TCr 14TCr 1.15TCr 1.13TCr 51TCr 316.38Cr 276.58Cr 254.17Cr 236.92Cr 449.37Cr 30TCr 456.18Cr 3.05TCr 1.19TCr 15TCr 1.19TCr 1.16TCr
Logo Nipro Corporation
Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.
Employees
39,168
Date Price Change Volume
03/26/03 JP¥1,558.50 -0.48% 4,56,000
02/26/02 JP¥1,566.00 +2.09% 6,93,900
01/26/01 JP¥1,534.00 -2.70% 7,04,000
30/26/30 JP¥1,576.50 -2.23% 6,66,800
29/26/29 JP¥1,612.50 +0.44% 5,43,100
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,558.50JPY
Average target price
1,876.00JPY
Spread / Average Target
+20.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 8086 Stock